EP0797454A4 - Improved adenoviral vectors and producer cells - Google Patents

Improved adenoviral vectors and producer cells

Info

Publication number
EP0797454A4
EP0797454A4 EP95943705A EP95943705A EP0797454A4 EP 0797454 A4 EP0797454 A4 EP 0797454A4 EP 95943705 A EP95943705 A EP 95943705A EP 95943705 A EP95943705 A EP 95943705A EP 0797454 A4 EP0797454 A4 EP 0797454A4
Authority
EP
European Patent Office
Prior art keywords
adenoviral vectors
producer cells
improved adenoviral
improved
producer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95943705A
Other languages
German (de)
French (fr)
Other versions
EP0797454A1 (en
Inventor
Michael Kadan
Mario Goziglia
Bruce Trapnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Therapy Inc
Original Assignee
Genetic Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Therapy Inc filed Critical Genetic Therapy Inc
Publication of EP0797454A1 publication Critical patent/EP0797454A1/en
Publication of EP0797454A4 publication Critical patent/EP0797454A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/70—Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95943705A 1994-12-12 1995-12-07 Improved adenoviral vectors and producer cells Withdrawn EP0797454A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35508794A 1994-12-12 1994-12-12
US355087 1994-12-12
US45840395A 1995-06-02 1995-06-02
US458403 1995-06-02
PCT/US1995/015947 WO1996018418A1 (en) 1994-12-12 1995-12-07 Improved adenoviral vectors and producer cells

Publications (2)

Publication Number Publication Date
EP0797454A1 EP0797454A1 (en) 1997-10-01
EP0797454A4 true EP0797454A4 (en) 2001-12-05

Family

ID=26998695

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95943705A Withdrawn EP0797454A4 (en) 1994-12-12 1995-12-07 Improved adenoviral vectors and producer cells

Country Status (6)

Country Link
EP (1) EP0797454A4 (en)
JP (1) JPH10510987A (en)
AU (1) AU709498B2 (en)
CA (1) CA2206683A1 (en)
NZ (1) NZ300387A (en)
WO (1) WO1996018418A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336587T1 (en) * 1994-06-10 2006-09-15 Genvec Inc ADENOVIRUS VECTOR SYSTEMS AND CELL LINES
DE69534166T2 (en) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania RECOMBINANT ADENOVIRUS AND METHODS OF USE THEREOF
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1998032860A1 (en) * 1997-01-28 1998-07-30 Baxter International Inc. Methods for highly efficient generation of adenoviral vectors
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
WO1998059063A2 (en) * 1997-06-23 1998-12-30 University Of Saskatchewan Bovine adenovirus type 3 genome
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7026164B2 (en) 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
CN1863918B (en) 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 Packaging cells for recombinant adenoviruses
CN103237889B (en) 2010-08-16 2017-04-05 萨克生物研究学院 Adenovirus assembly method
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
EP3188762A4 (en) 2014-07-31 2018-01-10 The Board of Regents of the University of Oklahoma High isomerohydrolase activity mutants of mammalian rpe65
KR102608590B1 (en) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 Oncolytic tumor viruses and methods of use
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS DIRECTIVE TO TUMORS AND USES THEREOF
CN112292449A (en) 2018-04-09 2021-01-29 萨克生物研究学院 Oncolytic adenovirus compositions with enhanced replication properties
MX2021014525A (en) * 2019-05-30 2022-03-17 Gritstone Bio Inc MODIFIED ADENOVIRUSES.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
WO1995034671A1 (en) * 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
WO1996010088A1 (en) * 1994-09-27 1996-04-04 Rhone-Poulenc Rorer S.A. DEFFECTIVE RECOMBINANT ADENOVIRUSES WITH INACTIVATED IVa2 GENE
WO1996013596A1 (en) * 1994-10-28 1996-05-09 Rhone-Poulenc Rorer S.A. Viable contaminant particle free adenoviruses, their preparation and use
WO1996014061A1 (en) * 1994-11-03 1996-05-17 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1024198A3 (en) * 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
FR2705686B1 (en) * 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
WO1995034671A1 (en) * 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
WO1996010088A1 (en) * 1994-09-27 1996-04-04 Rhone-Poulenc Rorer S.A. DEFFECTIVE RECOMBINANT ADENOVIRUSES WITH INACTIVATED IVa2 GENE
WO1996013596A1 (en) * 1994-10-28 1996-05-09 Rhone-Poulenc Rorer S.A. Viable contaminant particle free adenoviruses, their preparation and use
WO1996014061A1 (en) * 1994-11-03 1996-05-17 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARMENTANO D ET AL: "Second generation adenovirus vectors for cystic fibrosis gene therapy.", JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT, no. 18 PART A, 1994, Keystone Symposium on Gene Therapy;Copper Mountain, Colorado, USA; January 15-22, 1994, pages 222, XP001000902, ISSN: 0733-1959 *
BRIDGE E ET AL: "ADENOVIRUS EARLY REGION 4 AND VIRAL DNA SYNTHESIS", VIROLOGY,US,ACADEMIC PRESS,ORLANDO, vol. 193, no. 2, 1 April 1993 (1993-04-01), pages 794 - 801, XP002051623, ISSN: 0042-6822 *
G KETNER ET AL: "Complementation of adenovirus E4 mutants by transient expression of E4 cDNA and deletion plasmids", NUCLEIC ACIDS RESEARCH,IRL PRESS LTD., OXFORD,GB, vol. 17, no. 8, 1989, pages 3037 - 3048, XP002003252, ISSN: 0305-1048 *
GORZIGLIA M I ET AL: "GENERATION OF AN ADENOVIRUS VECTOR LACKING E1, E2A, E3, AND ALL OF E4 EXCEPT OPEN READING FRAME 3", JOURNAL OF VIROLOGY,THE AMERICAN SOCIETY FOR MICROBIOLOGY,US, vol. 73, no. 7, July 1999 (1999-07-01), pages 6048 - 6055, XP000939338, ISSN: 0022-538X *
See also references of WO9618418A1 *

Also Published As

Publication number Publication date
AU709498B2 (en) 1999-09-02
AU4511196A (en) 1996-07-03
WO1996018418A1 (en) 1996-06-20
NZ300387A (en) 2001-07-27
JPH10510987A (en) 1998-10-27
CA2206683A1 (en) 1996-06-20
EP0797454A1 (en) 1997-10-01

Similar Documents

Publication Publication Date Title
EP0797454A4 (en) Improved adenoviral vectors and producer cells
GB2290163B (en) Electrochemical cell
IL128882A0 (en) Viral vectors and their uses
TW441662U (en) Cell material structure
IL105341A0 (en) Solid electrolyte
GB2333453B (en) Colostrinin and uses thereof
GB9405406D0 (en) Atm cell switch
GB9520954D0 (en) Electrochemical cell
GB9621501D0 (en) Improved ATM
GB9613020D0 (en) Atm partial cut-through
GB2288297B (en) B-ISDN access
GB9618595D0 (en) Reaction cell
GB2286285B (en) Electrochemical cell
GB9426441D0 (en) Electrochemical cell
IL114688A0 (en) Vectors and transformed host cells
GB9605453D0 (en) Cultured cells
GB9608567D0 (en) Material carrying case
ZA9510933B (en) Electrochemical cell
GB2352176B (en) Colostrinin and uses thereof
GB2328118B (en) ATM cell switch
GB9016031D0 (en) Cell lysis
GB9608125D0 (en) Vectors
GB9607392D0 (en) Cell modification
GB9526091D0 (en) Improved hydrogen storage material
GB9625325D0 (en) Improved electrolytic cells and components therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 48/00 A, 7C 12N 15/00 B, 7C 07K 5/12 B

A4 Supplementary search report drawn up and despatched

Effective date: 20011019

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030701